SUMMARY In a double blind endoscopically controlled study, 100 patients with gastric ulcers were treated with either ranitidine or ranitidine plus Caved-S. On single therapy, 58% of ulcers were healed at four weeks, 92% at eight weeks and 96% at 12 weeks. Combination therapy did not alter the healing rate, nor improve on the control of dyspeptic symptoms. No difference in healing rate was found between good and poor drug compliance patients. This suggests that ranitidine may be equally effective at lower dosages. Thirty seven patients had developed their ulcer while taking non-steroidal anti-inflammatory drugs. These patients were mainly elderly women who had a higher risk of bleeding (p=0.006) from a large ulcer (p=0009).
In a previous study' we showed that cimetidine and Caved-S were equally effective in the treatment of gastric ulceration. As a gastric ulcer takes almost twice as long to heal as a duodenal ulcer, we suggested that combination therapy using an H2 receptor antagonist and a cytoprotective agent should be tried. This paper gives the results of such a study.
Methods

PATI ENTS
One hundred patients with endoscopically proven benign gastric ulcers not already on an ulcer healing agent were entered into the study. They were randomly allocated to treatment with either ranitidine 150 mg twice daily plus Caved-S two tablets three times a day, or ranitidine 150 mg twice daily plus placebo Caved-S two tablets three times a day. Antacid therapy was limited to Rennies. Each patient was asked to record daily on a diary card antacid consumption, and the presence or absence of pain.
Endoscopy was repeated at four weekly intervals until ulcer healing was achieved. A treatment failure was defined as an ulcer unhealed after 12 weeks treatment, complications of drug therapy or uncontrollable symptoms.
Before each endoscopy, haematological and biochemical safety screening was carried out, any side effects of treatment were noted and a return drug count undertaken.
All patients gave informed consent and the study was approved by the local hospital ethical committee.
STATISTICAL METHODS
Healing rates were compared between treatments using a log rank test from a life table analysis. The proportions of patients with healed ulcers at four weeks were compared between levels for the baseline factors (Table 1) using tests based on the x2 test.
Healing rates within levels of each of 21 possible pairs of baseline factors were calculated using a logistic model fitted to the counts in each two way table using a GLIM program to look for the presence of interactions between these factors.
Results
One hundred patients were entered into the study between August 1981 and October 1983. The two treatment groups were evenly matched with regard to the principal characteristics ( Table 1 ). The healing rates for the two treatment groups were similar with a mean value of 58% healed at four weeks, 87% at eight weeks and 95% at 12 weeks (Table 2) .
No clinically significant side effects were seen. Diary card analysis showed similar results for both treatment groups with good control of pain by the end of the first week of treatment ( Figure) .
Thirty seven per cent of the patients were taking non-steroidal anti-inflammatory (NSAI) drugs before the diagnosis of the ulcer. These patients were slightly older, with a higher female/male ratio, and a higher incidence of acute bleeding from a large ulcer (Table 3) .
Drug compliance for the first month of therapy was available for 85 patients. Sixteen returned more than five days supply, seven from the single therapy group (mean 8-6 days) and nine from the combined group (mean 8.4 days). Healing rates were not affected by compliance ( Table 2 ). The ratio of ulcer size was similar for the two groups.
Of the factors listed in Table 1 , only initial ulcer size was found to affect healing rates, with larger ulcers taking longer than small ulcers (p<O-OOl). The effect on healing rates for each of the 21 possible pairs of attributes were calculated. The only significant finding was that in the group of patients who had taken NSAI drugs, the proportion of women with healed ulcers at four weeks (nine out of 29) was less than for the men (eight out of eight) (p<O-OOl). This difference may be explained by the fact that 18 out of the 29 women had a large ulcer (62%) compared with only one out of eight men (13%). Before Treatment week treatment treated with either ranitidine or cimetidine, the healing rates for pirenzipine, DeNol, sucrulfate, carbenoxolone and Caved-S are similar. 1-1O As gastric ulcers take longer to heal than duodenal ulcers, drug combinations have been tried. The combination of cimetidine with antacids1" or anticholinergics12 has been used without success. Minoli et al combined cimetidine with carbenoxolone and showed a non-significant trend at three weeks in favour of the dual therapy.13
In 1982 we showed that cimetidine and Caved-S were equally effective in healing gastric ulcers' and suggested combination therapy. In this study, ranitidine has been compared with ranitidine plus Caved-S, and no beneficial effect was shown. The healing rate for the ranitidine only group was similar to other studies and no significant side effects were encountered. Both treatment regimes were equally effective in controlling symptoms. This study has shown the importance of nonsteroidal anti-inflammatory (NSAI) drugs in the pathogenesis of gastric ulceration. Thirty seven per cent of our patients were on such drugs, of whom slightly over 75% were women. We also confirm previous reports in which NSAI drug treatment has been shown to result in large ulcers which bleed.1 14 Ulcer healing rate is, however, the same for drug-related and non-drug-related ulcers. The only attributes found to affect ulcer healing was ulcer size, large ulcers, as would be expected, take longer to heal than small or medium sized ulcers (p<O.OOl).
The return drug count was available for 85 patients. The healing rate for the group of poor compliance patients was similar to the good tablet takers, and this suggests that the effect of ranitidine may be maximal at a dose smaller than 150 mg bd.
As the combination of ranitidine and Caved-S has failed to accelerate gastric ulcer healing, it will be interesting to see if treatment with the new synthetic prostaglandins will be any more effective. In the meantime, ranitidine, cimetidine or Caved-S would seem to remain the drugs of choice in gastric ulcer therapy. 
